Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | WDR5 | P61964 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10284256 | 0.89 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP1A2BACE1 | |
| SCHEMBL2600097 | 0.84 | MAP4K4 (0.40) | CYP2C19CYP3A4CYP2C9CYP1A2BACE1 | |
| SCHEMBL2600102 | 0.79 | CYP3A4 (0.50) | CYP2C19CYP3A4CYP2C9CYP1A2 | |
| SCHEMBL2600099 | 0.78 | CYP3A4 (0.49) | CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL10284080 | 0.77 | CYP3A4 (0.42) | CYP2C19CYP3A4CYP2C9CYP1A2 | |
| SCHEMBL2600096 | 0.77 | CYP3A4 (0.51) | CYP2C19CYP3A4CYP2C9CYP1A2 | |
| SCHEMBL2600075 | 0.77 | CYP3A4 (0.54) | CYP2C19CYP3A4CYP2C9CYP1A2 | |
| SCHEMBL10284257 | 0.76 | CYP3A4 (0.51) | CYP2C19CYP3A4CYP2C9CYP1A2 | |
| SCHEMBL2600093 | 0.76 | CYP3A4 (0.52) | CYP2C19CYP3A4CYP2C9CYP1A2 | |
| SCHEMBL2600095 | 0.76 | CYP3A4 (0.40) | CYP2C19CYP3A4CYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158636-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090286782-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286782-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PRKDC, PRKACA, PRKACG | CYP2C19 3085/4885CYP3A4 3734/4885CYP2C9 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.